November 28th 2023
Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States
January 12th 2022As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.
Wayne Winegarden, PhD: Why Competition Is Urgently Needed for Enbrel, Humira
December 12th 2021Etanercept and adalimumab biosimilar competition is not only necessary to drive down prices, it’s long overdue, according to Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute.
Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro
October 11th 2021Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).
Medicines for Europe Experts Discuss EU Market for Biosimilars, Part I
September 28th 2021Adrian van den Hoven, director general for Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, discuss the group’s recent EU report: Market Review—Biosimilar Medicine Markets.
Cardinal Health Biosimilars Expert Discusses Dynamics of Byooviz Launch
September 24th 2021The first ranibizumab biosimilar (Byooviz) has potential to alleviate financial burden associated with retinal conditions, but may not be the only new approval for ophthalmology treatment in 2022, explains Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health.
AAO Reacts to Ranibizumab Biosimilar Approval
September 23rd 2021The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.
Axinn’s Landmon Provides an Expert Legal Opinion on HHS’ Drug Price Strategy
September 22nd 2021The HHS plan ordered up by President Biden for combatting high drug prices is a hodgepodge of ideas that have long circulated in Washington, DC, but can any of them be made to stick? An intellectual property and FDA policy expert, Chad Landmon, JD, shares his perspective.
Chad Pettit, MBA, Discusses Amgen’s Biosimilar Trends Report and the Future of Biosimilars in the US
August 18th 2021Chad Pettit, MBA, executive director of Marketing and the Global Biosimilars commercial lead for Amgen, discussed the company’s 2021 Biosimilar Trends Report and his projections for the future of the biosimilars market.
Neal Dave, PharmD, Discusses What Clinics Need to Do to Ensure Biosimilars Are Cost-efficient
August 9th 2021Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.
Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars
July 18th 2021On this week’s episode of Not So Different, we spoke with David Senior, senior vice president of Market Economics at AmerisourceBergen, about the development of the generics market and how this could be instructive in understanding how biosimilars sales may develop.